At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 116 enrolled
Drug / intervention
Leuprorelin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase III Study to Assess the Impact of Transient Androgenic Deprivation With Enantone LP 11.25 Mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating Leuprorelin and Bicalutamide for Prostate Cancer. Completed, enrolled 116 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess two treatment strategies (leuprorelin treatment and active surveillance without androgen deprivation) for indolent prostate cancer and to compare their therapeutic benefit for management of patients with low-risk, localized prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedMar 2014
Primary CompletionNov 2016
TodayJul 2026
First PostedMar 12, 2014
Enrollment StartJun 3, 2013
Primary CompletionNov 8, 2016
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 12.3 years ago
Interventions
Leuprorelindrug
Solution for injection
Bicalutamidedrug
Bicalutamide tablets